SMS Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
SMS Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹5.4B ve toplam borcu ₹2.8B olup, bu da borç-öz sermaye oranını 52.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹10.3B ve ₹5.0B dir. SMS Pharmaceuticals 'in FAVÖK'ü ₹917.4M faiz karşılama oranı 4.2 dur. Şirketin ₹362.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
52.4%
Borç/özkaynak oranı
₹2.81b
Borç
| Faiz karşılama oranı | 4.2x |
| Nakit | ₹362.03m |
| Eşitlik | ₹5.36b |
| Toplam yükümlülükler | ₹4.98b |
| Toplam varlıklar | ₹10.34b |
Son finansal sağlık güncellemeleri
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09
Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: SMSPHARMA 'nin kısa vadeli varlıkları ( ₹5.3B ) kısa vadeli yükümlülüklerini ( ₹3.3B ) aşıyor.
Uzun Vadeli Yükümlülükler: SMSPHARMA şirketinin kısa vadeli varlıkları ( ₹5.3B ) uzun vadeli yükümlülüklerini ( ₹1.7B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: SMSPHARMA 'nin net borç/öz sermaye oranı ( 45.6% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: SMSPHARMA şirketinin borç/öz sermaye oranı son 5 yılda 42.4% seviyesinden 52.4% seviyesine yükseldi.
Borç Kapsamı: SMSPHARMA 'nin borcu işletme nakit akışı ( 17.9% ) tarafından iyi bir şekilde karşılanmıyor.
Faiz Kapsamı: SMSPHARMA 'in borcuna ilişkin faiz ödemeleri EBIT ( 4.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.